| | CEOP/IVE/GDP (N = 51) | CEOP (N = 51) |
|---|
| Grade 1–2 | Grade 3 | Grade 4 | Grade 1–2 | Grade 3 | Grade 4 |
|---|
| Hematological event |
| Neutropenia | 11 (22%) | 9 (18%) | 22 (43%) | 12 (24%) | 9 (18%) | 23 (45%) |
| Thrombocytopenia | 12 (24%) | 2 (4%) | 2 (4%) | 10 (20%) | 1 (2%) | 3 (6%) |
| Anemia | 34 (67%) | 4 (8%) | 1 (2%) | 31 (61%) | 5 (10%) | 0 |
| Febrile neutropenia | / | 10 (20%) | 0 | / | 12 (24%) | 2 (4%) |
| Non-hematological events |
| Infection* | 9 (18%) | 4 (8%) | 2 (4%) | 10 (20%) | 6 (12%) | 1 (2%) |
| Nausea or vomiting | 15 (29%) | 2 (4%) | 0 | 19 (37%) | 1 (2%) | 0 |
| ALT or AST increase | 9 (18%) | 2 (4%) | 0 | 8 (16%) | 1 (2%) | 0 |
| Mucositis | 13 (25%) | 0 | 0 | 15 (29%) | 1 (2%) | 0 |
| Fatigue | 37 (73%) | 1 (2%) | 0 | 34 (67%) | 1 (2%) | 0 |
| Headache | 13 (25%) | 1 (2%) | 0 | 5 (10%) | 1 (2%) | 0 |
- Data are n (%). All patients who received at least one dose of study drug were included in the safety analysis. *One patient in CEOP group died from severe infection after 1 cycle of treatment. ALT alanine aminotransferase, AST aspartate transaminase
